Table 2.
Multivariate regression analysis for identifying metastases.
| Variables | OR (95% CI) | P value |
|---|---|---|
| Age | 0.040 | |
| < 59.5 | 1.0 | |
| ≥ 59.5 | 2.269 (1.031–4.963) | |
| Gender | 0.002 | |
| Female | 1.0 | |
| Male | 3.511 (1.570–7.848) | |
| CT values in UP | < 0.001 | |
| < 27.5 | 1.0 | |
| ≥ 27.5 | 6.968 (2.580–18.824) | |
| Cystic degeneration/necrosis | 0.031 | |
| No | 1.0 | |
| Yes | 3.076 (1.110–8.521) | |
| ERV | < 0.001 | |
| > 1.44 | 1.0 | |
| ≤ 1.44 | 4.835 (2.006–11.694) | |
| Peak enhancement phase | ||
| Arterial phase | 1.0 | < 0.001 |
| Venous phase | 16.907 (4.319–66.182) | < 0.001 |
| Equally enhanced | 14.036 (3.429–57.455) | < 0.001 |
| Clinical stage of lung cancer | ||
| I | 1.0 | 0.001 |
| II | 3.550 (0.496–25.433) | 0.208 |
| III | 17.535 (2.959–103.905) | 0.002 |
| IV | 20.241 (3.532–116.007) | 0.001 |
OR, odds ratio; CI, confidence interval; UP, unenhanced phase; ERV, enhancement ratio on venous phase.